ArticleFrontiers in public health2021
ESBL Producing
Article in Frontiers in public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Review
- Fecal sludge and adjacent drinking water as reservoirs of multidrug resistant ESBL-producing pathogenic Escherichia coli in Rohingya Camps, Bangladesh.Scientific reports · 2026Article
- Article
- Prevalence and molecular characterization of multi-drug and extreme drug resistant Escherichia coli in companion animals in Bangladesh.Scientific reports · 2025Article
- Effects of household concrete floors on maternal and child health: the CRADLE trial - a randomised controlled trial protocol.BMJ open · 2025Article
- Multidrug-resistant ESBLHeliyon · 2025Article
- Hypo-osmotic stress is an anticipatory trigger of heat-resistance in presumptive extraintestinal pathogenicFrontiers in microbiology · 2025Article
- Isolation and characterization of cefotaxime resistantHeliyon · 2024Article
- Effects of household concrete floors on maternal and child health - the CRADLE trial: a randomised controlled trial protocol.medRxiv : the preprint server for health sciences · 2024Article
- Multidrug-resistantHeliyon · 2023Article
- Extended-Spectrum β-Lactamases (ESBL): Challenges and Opportunities.Biomedicines · 2023Review
- Molecular Characterization and Prevalence of Antimicrobial-ResistantMicroorganisms · 2023Article
- Article
- Healthcare Facilities as Potential Reservoirs of Antimicrobial ResistantPharmaceuticals (Basel, Switzerland) · 2022Article
- Genomic Characterization of International High-Risk Clone ST410Antibiotics (Basel, Switzerland) · 2022Article
- Article
- Antimicrobial-ResistantFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.